Nevro Stock Forecast, Price & News

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVRO shares have increased by 64.3% and is now trading at $180.42.
View which stocks have been most impacted by COVID-19.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Nevro stock.
View analyst ratings for Nevro or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Nevro a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nevro wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

6,978 employees have rated Nevro CEO Larry J. Merlo on Glassdoor.com. Larry J. Merlo has an approval rating of 37% among Nevro's employees. This puts Larry J. Merlo in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Nevro.

Nevro will be holding an earnings conference call on Wednesday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Nevro Corp. (NYSE:NVRO) released its quarterly earnings data on Thursday, November, 5th. The medical equipment provider reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.30. The medical equipment provider earned $108.46 million during the quarter, compared to analyst estimates of $104 million. Nevro had a negative net margin of 24.46% and a negative return on equity of 30.25%. The firm's revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.58) earnings per share.
View Nevro's earnings history.

Nevro updated its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $109.7-109.7 million, compared to the consensus revenue estimate of $106.54 million.

13 Wall Street analysts have issued twelve-month price targets for Nevro's stock. Their forecasts range from $100.00 to $215.00. On average, they expect Nevro's stock price to reach $178.92 in the next year. This suggests that the stock has a possible downside of 0.8%.
View analysts' price targets for Nevro or view Wall Street analyst' top-rated stocks.

Some companies that are related to Nevro include Insulet (PODD), Teleflex (TFX), NovoCure (NVCR), Abiomed (ABMD), Penumbra (PEN), iRhythm Technologies (IRTC), Hill-Rom (HRC), Globus Medical (GMED), Haemonetics (HAE), Inspire Medical Systems (INSP), Integra LifeSciences (IART), Tandem Diabetes Care (TNDM), Inari Medical (NARI), ICU Medical (ICUI) and ShockWave Medical (SWAV).
View all of NVRO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.03%) and Cutler Group LP (0.00%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold Nevro company stock in the last year include Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro or view top insider-selling stocks.

NVRO stock was bought by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle.
View insider buying and selling activity for Nevro or or view top insider-buying stocks.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $180.42.

Nevro has a market capitalization of $6.21 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 853 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]